Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for acetazolamide

  1. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  2. Cataracts in adults: management (NG77)

    This guideline covers managing cataracts in adults aged 18 and over. It aims to improve care before, during and after cataract surgery by optimising service organisation, referral and surgical management, and reducing complications. It further aims to improve the availability of information for people with cataracts before, during and after cataract surgery.

    NICE guideline
    Published
    26 October 2017
    View recommendations

    Sections for NG77

  3. Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)

    Evidence-based recommendations on latanoprost–netarsudil (Roclanda) for previously treated primary open-angle glaucoma or ocular hypertension in adults.

    Technology appraisal guidance
    Published
    2 October 2024
    View recommendations

    Sections for TA1009

  4. Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

    Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.

    Technology appraisal guidance
    Published
    1 December 2021
    View recommendations

    Sections for TA748

  5. Interventions to manage cystoid macular oedema:- What is the most effective postoperative medical management for cystoid macular oedema?

    macular oedema, no evidence has been identified for interventions such as acetazolamide, steroid-based anti-inflammatory drugs or...

    Research recommendation
    Published
    18 October 2018